IL257740A - Medicinal compounds for pain and their synthesis - Google Patents

Medicinal compounds for pain and their synthesis

Info

Publication number
IL257740A
IL257740A IL257740A IL25774018A IL257740A IL 257740 A IL257740 A IL 257740A IL 257740 A IL257740 A IL 257740A IL 25774018 A IL25774018 A IL 25774018A IL 257740 A IL257740 A IL 257740A
Authority
IL
Israel
Prior art keywords
pain
synthesis
therapeutic compounds
therapeutic
compounds
Prior art date
Application number
IL257740A
Other languages
English (en)
Hebrew (he)
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of IL257740A publication Critical patent/IL257740A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • C07D451/06—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • C07D451/06—Oxygen atoms
    • C07D451/10—Oxygen atoms acylated by aliphatic or araliphatic carboxylic acids, e.g. atropine, scopolamine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • C07D451/06—Oxygen atoms
    • C07D451/12—Oxygen atoms acylated by aromatic or heteroaromatic carboxylic acids, e.g. cocaine

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Pyridine Compounds (AREA)
IL257740A 2015-09-04 2018-02-26 Medicinal compounds for pain and their synthesis IL257740A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562214734P 2015-09-04 2015-09-04
US201562214727P 2015-09-04 2015-09-04
PCT/US2016/049871 WO2017040764A1 (en) 2015-09-04 2016-09-01 Therapeutic compounds for pain and synthesis thereof

Publications (1)

Publication Number Publication Date
IL257740A true IL257740A (en) 2018-04-30

Family

ID=58188341

Family Applications (5)

Application Number Title Priority Date Filing Date
IL257732A IL257732B (en) 2015-09-04 2018-02-26 1-((6-Methoxynaphthalen-2-yl)methyl)-4-(3,3,3-trifluoropropanoyl)-octahydro-1h-6,2-methanopyrrolo[3,2-b]pyridin-3-yl pivalate and synthesis His
IL257740A IL257740A (en) 2015-09-04 2018-02-26 Medicinal compounds for pain and their synthesis
IL257735A IL257735B (en) 2015-09-04 2018-02-26 4-(3,3,3-trifluoropropanoyl)octahydro-h1-6,2-methanopyrrolo[3,2-b]pyridin-3-yl pivalates and their synthesis
IL257734A IL257734B (en) 2015-09-04 2018-02-26 -(cyclopropylmethyl)-4-(3,3,3-trifluoropropanoyl)octahydro-1h-6,2-methanopyrrolo[3,2-b]pyridin-3-ylpivalates and their synthesis
IL257737A IL257737B2 (en) 2015-09-04 2018-02-26 Methanopyrrolo-pyridine-carboxylate based therapeutic compounds and synthesis thereof

Family Applications Before (1)

Application Number Title Priority Date Filing Date
IL257732A IL257732B (en) 2015-09-04 2018-02-26 1-((6-Methoxynaphthalen-2-yl)methyl)-4-(3,3,3-trifluoropropanoyl)-octahydro-1h-6,2-methanopyrrolo[3,2-b]pyridin-3-yl pivalate and synthesis His

Family Applications After (3)

Application Number Title Priority Date Filing Date
IL257735A IL257735B (en) 2015-09-04 2018-02-26 4-(3,3,3-trifluoropropanoyl)octahydro-h1-6,2-methanopyrrolo[3,2-b]pyridin-3-yl pivalates and their synthesis
IL257734A IL257734B (en) 2015-09-04 2018-02-26 -(cyclopropylmethyl)-4-(3,3,3-trifluoropropanoyl)octahydro-1h-6,2-methanopyrrolo[3,2-b]pyridin-3-ylpivalates and their synthesis
IL257737A IL257737B2 (en) 2015-09-04 2018-02-26 Methanopyrrolo-pyridine-carboxylate based therapeutic compounds and synthesis thereof

Country Status (11)

Country Link
US (9) US10040795B2 (enExample)
EP (5) EP3344628B9 (enExample)
JP (5) JP6868008B2 (enExample)
CN (5) CN108290890B (enExample)
CA (5) CA2997543C (enExample)
DK (4) DK3344628T5 (enExample)
ES (4) ES2807901T3 (enExample)
IL (5) IL257732B (enExample)
MA (1) MA45011A (enExample)
TW (11) TWI663167B (enExample)
WO (5) WO2017040764A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2997543C (en) * 2015-09-04 2022-07-19 Janssen Pharmaceutica Nv Therapeutic compounds for pain and synthesis thereof

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1469781A (en) * 1974-06-10 1977-04-06 Boehringer Sohn Ingelheim Production of scopine
US4232026A (en) * 1978-07-20 1980-11-04 Merck & Co., Inc. Diazaditwistanes, and pharmaceutical compositions for treating pain in warm blooded animals containing them
US4559157A (en) 1983-04-21 1985-12-17 Creative Products Resource Associates, Ltd. Cosmetic applicator useful for skin moisturizing
LU84979A1 (fr) 1983-08-30 1985-04-24 Oreal Composition cosmetique ou pharmaceutique sous forme aqueuse ou anhydre dont la phase grasse contient un polyether oligomere et polyethers oligomeres nouveaux
US4532244A (en) * 1984-09-06 1985-07-30 Innes Margaret N Method of treating migraine headaches
US4820508A (en) 1987-06-23 1989-04-11 Neutrogena Corporation Skin protective composition
US4992478A (en) 1988-04-04 1991-02-12 Warner-Lambert Company Antiinflammatory skin moisturizing composition and method of preparing same
US4938949A (en) 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
CA2086434C (en) * 1990-07-23 1998-09-22 John A. Lowe, Iii Quinuclidine derivatives
EP0553264A4 (en) 1990-10-05 1994-07-13 Wayne M Barnes Thermostable dna polymerase
US6432976B1 (en) * 1999-10-29 2002-08-13 Merck & Co., Inc. 8-aza-bicyclo[3.2.1]octane NMDA/NR2B antagonists
DE10050994A1 (de) * 2000-10-14 2002-04-18 Boehringer Ingelheim Pharma Neue als Arneimittel einsetzbare Anticholinergika sowie Verfahren zu deren Herstellung
EP1626970B1 (en) * 2003-05-28 2009-07-08 Theravance, Inc. Azabicycloalkane compounds as muscarinic receptor antagonists
EP1678172B1 (en) * 2003-10-15 2009-12-09 Targacept, Inc. Azabicyclic compounds for relieving pain and treating central nervous system disorders
CN101248073A (zh) * 2005-08-22 2008-08-20 塔加西普特公司 杂芳基-取代的二氮杂三环烷类、其制备方法及其应用
US8735411B2 (en) * 2006-10-02 2014-05-27 Abbvie Inc. Macrocyclic benzofused pyrimidine derivatives
WO2008104955A1 (en) * 2007-02-28 2008-09-04 Ranbaxy Laboratories Limited Azoniatricyclo [3.3.1.0] nonane derivatives as muscarinic receptor antagonists
TW200840569A (en) * 2007-03-13 2008-10-16 Targacept Inc Sub-type selective amides of diazabicycloalkanes
WO2009124755A1 (en) * 2008-04-08 2009-10-15 European Molecular Biology Laboratory (Embl) Compounds with novel medical uses and method of identifying such compounds
CN101768158B (zh) * 2010-01-04 2013-05-29 南昌弘益科技有限公司 噻托溴铵无水物及其制备方法
CN102579458A (zh) * 2012-03-08 2012-07-18 冀中能源峰峰集团有限公司总医院 缓解静点药物所致疼痛和防治静脉炎的药品配方
JP6102122B2 (ja) * 2012-08-24 2017-03-29 ソニー株式会社 画像処理装置および方法、並びにプログラム
ES2602039T3 (es) * 2012-09-18 2017-02-17 Heptares Therapeutics Limited Compuestos aza bicíclicos como agonistas del receptor M1 muscarínico
TW201444849A (zh) * 2013-03-13 2014-12-01 Janssen Pharmaceutica Nv 經取代的7-氮雜雙環類及其作為食慾激素受體調節劑之用途
TWI627174B (zh) * 2013-03-14 2018-06-21 比利時商健生藥品公司 Ｐ２ｘ７調控劑
KR20160115503A (ko) * 2015-03-27 2016-10-06 차의과학대학교 산학협력단 만성 골수성 백혈병 암 줄기세포의 성장 또는 증식 억제용 조성물 및 이의 스크리닝 방법
GB201505654D0 (en) * 2015-04-01 2015-05-13 Nordic Bioscience As Immunoassay for collagen type VI sequence
GB201505701D0 (en) * 2015-04-02 2015-05-20 Byotrol Plc Anti-microbial composition
CA2997543C (en) * 2015-09-04 2022-07-19 Janssen Pharmaceutica Nv Therapeutic compounds for pain and synthesis thereof

Also Published As

Publication number Publication date
TWI672303B (zh) 2019-09-21
CN109153679B (zh) 2022-04-08
TWI641608B (zh) 2018-11-21
TWI654188B (zh) 2019-03-21
US9994572B2 (en) 2018-06-12
CA2997545C (en) 2022-01-11
CN109071540A (zh) 2018-12-21
CA2997430A1 (en) 2017-03-09
ES2808048T3 (es) 2021-02-25
JP2018526387A (ja) 2018-09-13
EP3344627B9 (en) 2021-08-04
EP3344626A1 (en) 2018-07-11
TWI713879B (zh) 2020-12-21
EP3344628A4 (en) 2019-03-27
US10351565B2 (en) 2019-07-16
TW201835082A (zh) 2018-10-01
US20180291024A1 (en) 2018-10-11
US20190112311A1 (en) 2019-04-18
EP3344626A4 (en) 2019-03-27
US10040795B2 (en) 2018-08-07
DK3344628T3 (da) 2020-08-03
US10351566B2 (en) 2019-07-16
EP3344629A1 (en) 2018-07-11
TW201811786A (zh) 2018-04-01
EP3344629A4 (en) 2019-03-27
TW201722951A (zh) 2017-07-01
CA2997543A1 (en) 2017-03-09
ES2809703T9 (es) 2022-01-24
CN109071540B (zh) 2021-06-04
CN108495854B (zh) 2021-10-15
US10040796B2 (en) 2018-08-07
EP3344627A1 (en) 2018-07-11
MA45011A (fr) 2021-06-02
EP3344626B1 (en) 2020-07-08
TWI683815B (zh) 2020-02-01
EP3344628A1 (en) 2018-07-11
CN109153679A (zh) 2019-01-04
CN108349934B (zh) 2021-10-22
CA2997501A1 (en) 2017-03-09
JP2018531907A (ja) 2018-11-01
TW201722955A (zh) 2017-07-01
WO2017040764A1 (en) 2017-03-09
EP3344627B1 (en) 2020-07-01
US20180327406A1 (en) 2018-11-15
CN108349934A (zh) 2018-07-31
CN108290890B (zh) 2021-08-06
US10155762B2 (en) 2018-12-18
EP3344614A4 (en) 2019-03-27
ES2808048T9 (es) 2022-02-01
EP3344628B1 (en) 2020-07-15
DK3344614T5 (da) 2021-08-30
ES2807901T9 (es) 2022-01-31
WO2017040772A9 (en) 2019-03-07
US10358448B2 (en) 2019-07-23
EP3344614B9 (en) 2021-07-28
TW201716409A (zh) 2017-05-16
CN108290890A (zh) 2018-07-17
JP2018526388A (ja) 2018-09-13
TWI686393B (zh) 2020-03-01
IL257734B (en) 2021-07-29
IL257737B (en) 2022-10-01
EP3344614A1 (en) 2018-07-11
TW201833110A (zh) 2018-09-16
JP2018527356A (ja) 2018-09-20
JP6736660B2 (ja) 2020-08-05
ES2812233T9 (es) 2022-02-18
DK3344626T3 (da) 2020-07-27
US20170066768A1 (en) 2017-03-09
WO2017040770A1 (en) 2017-03-09
EP3344628B9 (en) 2021-06-30
US20180327405A1 (en) 2018-11-15
WO2017040778A1 (en) 2017-03-09
DK3344627T3 (da) 2020-07-20
JP6639651B2 (ja) 2020-02-05
CN108495854A (zh) 2018-09-04
IL257734A (en) 2018-04-30
US20170066760A1 (en) 2017-03-09
CA2997541A1 (en) 2017-03-09
ES2807901T3 (es) 2021-02-24
TW201843153A (zh) 2018-12-16
EP3344614B1 (en) 2020-07-08
CA2997541C (en) 2022-01-11
TW201722954A (zh) 2017-07-01
TWI707854B (zh) 2020-10-21
IL257735B (en) 2022-01-01
DK3344627T5 (da) 2021-08-30
TW201722953A (zh) 2017-07-01
WO2017040767A1 (en) 2017-03-09
US20170066769A1 (en) 2017-03-09
TW201920176A (zh) 2019-06-01
TWI639597B (zh) 2018-11-01
DK3344626T5 (da) 2021-09-06
CA2997430C (en) 2021-05-11
IL257735A (en) 2018-04-30
CA2997545A1 (en) 2017-03-09
US20170066767A1 (en) 2017-03-09
IL257732A (en) 2018-04-30
IL257737B2 (en) 2023-02-01
JP6736661B2 (ja) 2020-08-05
TWI663167B (zh) 2019-06-21
JP6868008B2 (ja) 2021-05-12
TWI636054B (zh) 2018-09-21
WO2017040772A1 (en) 2017-03-09
JP2018527355A (ja) 2018-09-20
EP3344627A4 (en) 2019-03-27
ES2812233T3 (es) 2021-03-16
CA2997501C (en) 2022-05-10
IL257732B (en) 2020-11-30
EP3344626B9 (en) 2021-08-11
TW201819381A (zh) 2018-06-01
US10766898B2 (en) 2020-09-08
JP6736659B2 (ja) 2020-08-05
ES2809703T3 (es) 2021-03-05
TWI695836B (zh) 2020-06-11
IL257737A (en) 2018-04-30
US20170066770A1 (en) 2017-03-09
CA2997543C (en) 2022-07-19
US10040797B2 (en) 2018-08-07
DK3344614T3 (da) 2020-07-27
DK3344628T5 (da) 2021-07-26

Similar Documents

Publication Publication Date Title
IL258931A (en) Medicinal compounds and methods
GB201616839D0 (en) Therapeutic compounds
ZA201802256B (en) Compounds and therapeutic uses thereof
ZA201805046B (en) Therapeutic compounds
GB201716942D0 (en) Therapeutic compounds
GB201715194D0 (en) Compounds and their therapeutic use
GB201617064D0 (en) Compounds and their therapeutic use
IL270011B (en) Medicinal compounds and methods
GB201502412D0 (en) Therapeutic use
GB201608797D0 (en) Therapeutic use
GB201617339D0 (en) Therapeutic compounds
IL265269B (en) New compounds and their medicinal uses
GB201604658D0 (en) Treatment for pain
IL263821A (en) Medicinal compounds
IL257740A (en) Medicinal compounds for pain and their synthesis
GB201506786D0 (en) Therapeutic use
GB201712884D0 (en) Novel therapeutic compounds
GB201705684D0 (en) Novel compounds and therapeutic uses thereof
GB201712394D0 (en) Therapeutic compounds
GB201712388D0 (en) Therapeutic compounds
GB201712390D0 (en) Therapeutic compounds
GB201712395D0 (en) Therapeutic compounds
GB201712393D0 (en) Therapeutic compounds
GB201712392D0 (en) Therapeutic compounds
GB201705683D0 (en) Novel compounds and therapeutic uses thereof

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed